Truist Securities Reiterates Buy on Biomarin Pharmaceutical, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $140.
September 15, 2023 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical's stock has been reiterated as a 'Buy' by Truist Securities with a maintained price target of $140.
The reiteration of a 'Buy' rating by a reputable analyst like Robyn Karnauskas from Truist Securities is a positive signal for Biomarin Pharmaceutical. The maintained price target of $140 indicates that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100